Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Statins in NAFLD/NASH
NCT07180745Phase 4Not yet recruiting
- Sponsor
- Badr University in Cairo
- Start
- Nov 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (5 arms), sponsored by Badr University in Cairo. Primary endpoints: Controlled Attenuation Parameter at 3 months and Liver Stiffness Measurement at 3 months. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT07180745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07180745.